Efficacy of compound Xueshuantong capsule for non-proliferative diabetic retinopathy:a Meta-analysis
Objective To evaluate the efficacy of compound Xueshuantong capsule in the treatment of non-proliferative diabetic retinopathy(NPDR)systematically.Methods CNKI,Wanfang,VIP,Chinese Biology Medicine(CBM),Embase,PubMed and The Cochrane Library were searched by computer(the search time was from the establishment of the database to April 2022)to include the randomized controlled study of compound Xueshuantong capsule in the treatment of NPDR.Meta-analysis was performed using RevMan5.3 software after two analysts independently screened,read and extracted literature and assessed the risk of bias.Results A total of 8 articles were included,including 1048 patients.The results of Meta-analysis showed that compared with the control group,the experimental group could significantly improve the clinical efficacy of patients[RR=1.27,95%CI(1.18,1.36),P<0.00001],alleviate macular edema[MD=-26.27,95%CI(-35.72,-16.83),P<0.00001],and improve the hemodynamic indexes of ophthalmic artery[MDPSV=1.10,95%CI(0.82,1.39),P<0.00001;MDEDV=0.73,95%CI(0.60,0.86),P<0.00001;MDRI=-0.02,95%CI(-0.03,-0.01),P<0.00001];there was no significant difference between experimental group and control group in hemodynamic indexes of central retinal artery(P>0.05).Conclusion Compound Xueshuantong capsule can significantly improve the clinical efficacy of NPDR patients,alleviate macular edema,improve the hemodynamic indexes of ophthalmic artery,but has no significant improvement on the hemodynamic indexes of central retinal artery.
万方数据
维普
